Metastatic colorectal carcinoma : response to panitumuinab

Abstract EN

A 69-year-old British gentleman with a good performance status, who runs a charity for animals (important), presented to the Gastroenterology outpatient department at the Bahrain Specialist Hospital (June 2016) with complaints of vague abdominal discomfort, bloating sensation, tiredness, and a change in the bowel habits.

Endoscopy revealed a rectosigmoid colon mass, and the biopsy confirmed an invasive adenocarcinoma.

The elderly man received six cycles of combination chemotherapy with oxaliplatm and capecitabine (until January 2017); however, the disease progressed, and he had liver metastases.

A total mesenteric excision along with metastasectomy of the liver lesions was performed (February 2017); and a follow-up positron emission tomography-computed tomography (PET-CT) image showed a progressive disease with multiple lesions in both lobes of the liver as well as local recurrence.

He was depressed and wanted to know further options; and so, was started on injection panitumumab 6 mg/kg administered every 21 days.

After four doses of the therapy, PET-CT showed complete resolution of the local recurrence and partial resolution of the liver lesions.

The patient, then resumed his activities with a good performance status and the therapy with panitumumab will be continued until either, disease progression or severe side effects are observed.

The case illustrates the effectiveness of panitumumab m metastatic colorectal carcinoma, which has progressed on standard chemotherapy regimen.